Full compliance with Respiratory syncytial virus prophylaxis was associated with fewer respiratory-related hospital admissions in preterm children: A cohort study.
acute respiratory illness
hospital admissions
preterm children
prophylaxis
respiratory syncytial virus
Journal
Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
25
11
2020
received:
04
09
2020
accepted:
26
11
2020
pubmed:
30
11
2020
medline:
20
5
2021
entrez:
29
11
2020
Statut:
ppublish
Résumé
Although well documented in randomised trials, the efficacy of prophylaxis against respiratory syncytial virus (RSV) in real-word conditions is less studied. The objective was to assess the impact of partial versus full RSV prophylaxis for acute respiratory infections (ARIs) and ARI-related hospital admissions in preterm children. This study included children born preterm in 2011 in France who were eligible for RSV prophylaxis and received at least one palivizumab dose from October 2011 to March 2012. Full prophylaxis was defined as receiving at least one palivizumab dose for each month of RSV exposure in the community. Children with full and partial prophylaxis were matched, and odds of ARIs and ARI-related hospital admission were compared by logistic regression. Full prophylaxis concerned 861/1083 (80%) children. As compared with full prophylaxis, partial prophylaxis was not associated with ARI occurrence (odds ratio OR 1.3, 95% confidence interval CI 0.9-1.9) but was significantly associated with ARI-related hospital admission during the RSV epidemic (OR 1.9, 95% CI 1.2-2.9). During the 2011-2012 RSV epidemic, hospital admission rates were higher for preterm children with partial than full RSV prophylaxis. Improving compliance could help alleviate the burden of RSV on healthcare systems.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antiviral Agents
0
Palivizumab
DQ448MW7KS
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1633-1638Informations de copyright
©2020 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
Références
Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-1555.
Szabo SM, Gooch KL, Bibby MM, et al. The risk of mortality among young children hospitalized for severe respiratory syncytial virus infection. Paediatr Respir Rev. 2013;13(Suppl 2):S1-8.
Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;(4):CD006602. https://doi.org/10.1002/14651858.CD006602.pub4
Frogel MP, Stewart DL, Hoopes M, et al. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010;16(1):46-58.
Stewart DL, Ryan KJ, Seare JG, et al. Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured children: a retrospective claims analysis. BMC Infect Dis. 2013;13:334.
Krilov LR, Masaquel AS, Weiner LB, et al. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis. BMC Pediatr. 2014;14:261.
Chan P, Li A, Paes B, et al. Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian registry of palivizumab. Pediatr Infect Dis J. 2015;34(12):e290-e297.
Wu P, Escobar GJ, Gebretsadik T, et al. Effectiveness of respiratory syncytial virus immunoprophylaxis in reducing bronchiolitis hospitalizations among high-risk children. Am J Epidemiol. 2018;187(7):1490-1500.
Farber HJ, Buckwold FJ, Lachman B, et al. Observed effectiveness of palivizumab for 29-36-week gestation children. Pediatrics. 2016;138(2):e20160627.
Commission de la Transparence - AVIS 19 décembre 2007- Synagis. https://www.has-sante.fr/upload/docs/evamed/CT-15884_SYNAGIS_QD_INS_Avis2_CT15884.pdf. Accessed October 9, 2020
Torchin H, Rousseau J, Marchand-Martin L, et al. Palivizumab administration in preterm children in France: EPIPAGE-2 cohort study. Arch Pediatr. 2018;25(2):89-94.
Ancel P-Y, Goffinet F, EPIPAGE 2 Writing Group. EPIPAGE 2: a preterm birth cohort in France in 2011. BMC Pediatr. 2014;14(1):97.
Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723-1729.
Conférence de consensus sur la prise en charge de la bronchiolite du nourrisson. [Consensus conference on the management of infant bronchiolitis]. Arch Pediatr. 2001;8(Suppl 1):1s-196s.
Winterstein AG, Choi Y, Meissner HC. Association of age with risk of hospitalization for respiratory syncytial virus in preterm children with chronic lung disease. JAMA Pediatr. 2018;172(2):154-160.
Shi T, Balsells E, Wastnedge E, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020416.
Paes B, Mitchell I, Li A, et al. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol. 2013;2013:917068.
Parnes C, Guillermin J, Habersang R, et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003;35(6):484-489.
Lacaze-Masmonteil T, Rozé J-C, Fauroux B, et al. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of children treated with Palivizumab as RSV prophylaxis. Pediatr Pulmonol. 2002;34(3):181-188.
Mitchell I, Paes BA, Li A, et al. CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J. 2011;30(8):651-655.
Manzoni P, Paes B, Lanctôt KL, et al. Outcomes of children receiving palivizumab prophylaxis for RSV in Canada and Italy: an international, prospective, Cohort Study. Pediatr Infect Dis J. 2017;36(1):2-8.